NEW YORK--(BUSINESS WIRE)--Nov. 17, 2005--Bioenvision (Nasdaq:BIVN) today announced that the first patients have been enrolled and commenced treatment in three separate, clinical studies of Modrenal(R) (trilostane). These studies are investigating the efficacy of Modrenal in three distinct settings: (1) a Phase IV trial in advanced, post-menopausal breast cancer, (2) a Phase II trial in pre-menopausal breast cancer; and (3) a Phase II trial utilizing Modrenal(R) as a neo-adjuvant (pre-operative) treatment in post-menopausal breast cancer.
